Brief: Bioarctic - EC Refers Lecanemab Marketing Authorisation Decision To Appeal Committee
01/04/2025 11:20
April 1 (Reuters) - BioArctic AB BIOAb.ST: EC REFERS LECANEMAB MARKETING AUTHORISATION DECISION TO APPEAL COMMITTEE Source text: ID:nWkr8ywVZh Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million